Study Detail


ImpaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY)

Status: not available

Type: not available

Funder: not available

Sponsor: Royal Devon and Exeter NHS Foundation Trust

CI: Dr Tariq Ahmad

IRAS-Number: 283251

CPMS-ID: 46188

Approval Date: not available


The impact of immunosuppressive and immunomodulatory treatment on SARS-CoV-2 infection and disease severity is unknown, but is a major concern for patients and clinicians. Inflammatory bowel disease (IBD) affects about 1% of the UK population and is usually treated with immunosuppressive drugs. This study aims to define the impact of immunosuppressive drug therapy and physical distancing strategies on SARS-CoV-2 seroprevalence within this patient group. Although this study will define risk in IBD patients, there are potentially important lessons to be learned for millions of patients across the UK with other immune mediated diseases treated with similar therapies.

Back to listing